Clinical Study on the Modified Formula of Huang Yuanyu’s Gui Fu Ling Wu Decoction for Treating Spleen-Kidney Yang Deficiency Type Diabetic Nephropathy

Xiaoqin Liu, Xiaoping Zhou, Wen Wang, Meiji Li, Qian Zhang, Xiaoxia Zhai, Kexin Yu

Show Less

¹ Changyi Hospital of Traditional Chinese Medicine, Changyi 261300, Shandong Province, China,

JCNR 2025 , 9(1), 32–38; https://doi.org/10.26689/jcnr.v9i1.9476

© 2025 by the Authors. Licensee Whioce Publishing, Singapore. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Abstract

Objective: To evaluate the efficacy of the modified Gui Fu Ling Wu Decoction in treating diabetic nephropathy (DN) of the spleen-kidney Yang deficiency type. Methods: A total of 100 DN patients admitted to Changyi Traditional Chinese Medicine Hospital between August 2023 and March 2024 were included in the study. Patients were randomly divided into a control group and a study group, each comprising 50 cases, using a computerized random number generator. The control group received kallikrein treatment, while the study group received a combination of kallikrein and the modified Gui Fu Ling Wu Decoction. Blood glucose control, renal function, and inflammatory markers were assessed before and after treatment in both groups. Results: Before treatment, there were no significant differences in blood glucose and renal function indicators between the two groups (P > 0.05). After treatment, postprandial blood glucose, fasting blood glucose, 24-hour urinary protein, urinary microalbumin, serum creatinine, serum C-reactive protein (CRP), and interleukin-6 levels significantly decreased in both groups, with the study group showing superior results compared to the control group (P < 0.05). Conclusion: The combination of Gui Fu Ling Wu Decoction and kallikrein for treating spleen-kidney Yang deficiency type DN significantly improves blood glucose control, enhances renal function, and reduces inflammatory responses.

References

Selby NM, Taal MW, 2020, An Updated Overview of Diabetic Nephropathy: Diagnosis, Prognosis, Treatment Goals and Latest Guidelines. Diabetes Obes Metab, 22 Suppl 1: 3–15. https://doi.org/10.1111/dom.14007

Thipsawat S, 2021, Early Detection of Diabetic Nephropathy in Patient with Type 2 Diabetes Mellitus: A Review of the Literature. Diab Vasc Dis Res, 18(6): 14791641211058856. https://doi.org/10.1177/14791641211058856

Zhang Y, Huang A, Zhang L, 2023, Therapeutic Effect of Yishenkang on Early Diabetic Kidney Disease with Qi Yin Deficiency and Blood Stasis Syndrome and Its Effects on Inflammatory Factors. Journal of Liaoning University of Traditional Chinese Medicine, 25(1): 188–192.

Zhang J, Ren S, Zhang Y, et al., 2024, Huang Yuanyu’s Thought on Treating Uterine Bleeding from the Perspective of “Wood Qi Sinking” in Si Sheng Xin Yuan. Journal of Basic Chinese Medicine, 30(4): 572–574.

Chinese Medical Association Nephrology Section Expert Group, 2021, Chinese Guidelines for the Clinical Diagnosis and Treatment of Diabetic Kidney Disease. Chinese Journal of Nephrology, 37(3): 50.

Chinese Society of Traditional Chinese Medicine, 2011, Guidelines for the Prevention and Treatment of Diabetic Nephropathy in Traditional Chinese Medicine. Chinese Medicine Modern Distance Education of China, 9(4): 151–153.

Yang Y, Wang J, Ruan S, 2024, Exploring the Pathogenesis and Treatment of Chronic Kidney Disease Based on the Concept of “Qi Circulation and Earth Pivot Four Phases”. Acta Chinese Medicine, Online ahead of print. http://kns.cnki.net/kcms/detail/41.1411.R.20240805.1033.012.html

Huang Y, Huang G, Cai L, et al., 2019, Effect and Safety of Bailing Capsule Combined with RAAS Inhibitors in Treatment of Early Diabetic Nephropathy: A Systematic Review. Chinese Archives of Traditional Chinese Medicine, 37(6): 1290–1297.

Chen Z, Zhou H, Wu H, et al., 2019, Based on the Data Mining to Discuss the Theory of Diabetes from Si Sheng Xin Yuan. Guiding Journal of Traditional Chinese Medicine and Pharmacy, 25(7): 21–25 + 38.

Ng CYJ, Lai NPY, Ng WM, et al., 2024, Chemical Structures, Extraction and Analysis Technologies, and Bioactivities of Edible Fungal Polysaccharides from Poria cocos: An Updated Review. Int J Biol Macromol, 261(Pt 1): 129555. https://doi.org/10.1016/j.ijbiomac.2024.129555

Liu Y, Sun M, Yao H, et al., 2019, A Network Pharmacology Approach to Explore the Mechanisms of Traditional Chinese Medicine in Metabolic Syndrome. Modernization of Traditional Chinese Medicine and Materia Medica – World Science and Technology, 21(11): 2347–2355.

Liu M, Wang H, Liang R, et al., 2022, Compatibility Research of Drug Pair Poria-Alismatis Rhizoma and Its Effect on Nephropathy Model Rats. China Pharmacist, 25(8): 1317–1323.

Hu Y, Zeng C, Nie Y, 2024, Efficacy of Modified Yangyin Qingre Decoction on Yin Deficiency Type of Elderly Diabetic Nephropathy and Influence on Inflammatory Factors of CRP and IL-6. Journal of Sichuan of Traditional Chinese Medicine, 42(2): 134–137.

Wang Y, Yu H, Xu L, et al., 2024, Tangshen Guanchang Prescription Reduces Inflammation in Diabetic Kidney Disease via Regulating PI3K/AKT/NF-κB Signaling Pathway. Pharmacology and Clinics of Chinese Materia Medica, 40(3): 8–16.

Wang T, 2022, Clinical Observation on Treating Diabetic Kidney Disease in A3G3 Period by Qikui Granule Combined with Huobahuagen (HBHG) Tablets, dissertation, Nanjing University of Traditional Chinese Medicine.

Previous article in this issue

Next article in this issue